文献速递肾小球疾病慢性肾脏病

狼疮性肾炎肾脏缓解状态与长期肾脏结局

Long-Term Kidney Outcome of Lupus Nephritis by Renal Response Status.
PubMed 文献 · Kidney Int Rep · 2024-10-10

该回顾性队列研究纳入176例中国狼疮性肾炎患者,按活检后2年时改良肾脏缓解标准分组,发现达到mPERR或mCRR者长期肾脏存活率显著更高、CKD进展风险更低。

要点

  • 活检后2年达到mPERR或mCRR可预测更好的长期肾脏结局。
  • mPERR和mCRR与肾脏非存活风险分别降低60%和86%相关。
  • mPERR和mCRR与轻度CKD或更差风险分别降低82%和87%相关。

核心结论

  • 在中国狼疮性肾炎患者中,活检后2年达到mPERR或mCRR可预测更优的长期肾脏结局和更低的CKD进展风险。

研究设计与样本

  • 香港玛丽医院队列前瞻性收集数据的回顾性分析,纳入176例活检证实的狼疮性肾炎成年患者。
  • 患者接受标准治疗和免疫抑制诱导,活检后2年按mPERR和mCRR标准分组。

主要发现

  • 活检后2年64.2%达到mPERR,43.8%达到mCRR。
  • 平均随访15.3年,mPERR应答者长期肾脏存活率85.8% vs 非应答者71.4%(P=0.029)。
  • mCRR应答者长期肾脏存活率92.2% vs 非应答者71.7%(P<0.001)。
  • mPERR和mCRR与肾脏非存活调整风险降低60%(P=0.034)和86%(P<0.001)相关。
  • mPERR和mCRR与轻度CKD或更差(≥3期)调整风险降低82%(P=0.013)和87%(P=0.012)相关。

关键数值与推荐

  • mPERR:eGFR≥60 ml/min per 1.73 m2或较活检值下降≤20%,且uPCR≤0.7。
  • mCRR:eGFR≥90 ml/min per 1.73 m2或较活检值下降≤10%,且uPCR≤0.5。

临床怎么用

  • 活检后2年评估mPERR/mCRR可用于识别长期肾脏预后不良的高危狼疮性肾炎患者。
  • 未达到mPERR或mCRR者可能需要更密切监测和强化管理以延缓CKD进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Limited evidence exists that clinical trial treatment response criteria predict long-term outcomes in Asian patients with lupus nephritis (LN). METHODS: This retrospective analysis of prospectively collected data from the Hong Kong Queen Mary Hospital Cohort categorized adults with biopsy-proven LN (Class III, IV, V, or mixed [III ± V, IV ± V]) after standard treatment for 2 years postbiopsy and immunosuppression induction according to modified primary efficacy renal response (mPERR: estimated glomerular filtration rate [eGFR] ≥ 60 ml/min per 1.73 m2 or ≤ 20% below biopsy value AND urine protein-to-creatinine ratio [uPCR] ≤ 0.7) and modified complete renal response (mCRR; eGFR ≥ 90 ml/min per 1.73 m2 or ≤ 10% below biopsy value AND uPCR ≤ 0.5). Associations between 2-year mPERR/mCRR status and long-term kidney survival and mild chronic kidney disease (CKD) or worse (stage ≥ 3) were assessed. RESULTS: Of the 176 Chinese patients, 64.2% achieved mPERR and 43.8% achieved mCRR at 2 years postbiopsy. After mean follow-up of 15.3 years, significantly higher proportions of mPERR and mCRR responders versus nonresponders achieved long-term kidney survival (mPERR: 85.8% vs. 71.4%; P = 0.029; mCRR: 92.2% vs. 71.7%; P < 0.001). mPERR and mCRR achievement was associated with adjusted risk reductions for kidney nonsurvival of 60% (P = 0.034) and 86% (P < 0.001), respectively. Adjusted risk for mild CKD or worse (stage ≥ 3) was 82% (P = 0.013) and 87% (P = 0.012) lower for mPERR and mCRR responders, respectively, versus nonresponders. CONCLUSION: In Chinese patients with LN, mPERR and mCRR at 2 years postbiopsy predict superior long-term kidney outcomes and lower CKD progression risk.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Yap DYH, Xu X, Juliao PC, et al. Long-Term Kidney Outcome of Lupus Nephritis by Renal Response Status. Kidney Int Rep. 2024. PMID: 39698368. doi:10.1016/j.ekir.2024.09.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。